MeSH D012164 - retinal diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D005128:Eye diseases
0 Companies
0 Drugs
Success rate
D012164:
Retinal diseases
D000077765:Cone dystrophy
0 Companies
0 Drugs
Success rate
D000080345:Familial exudative vitreoretinopathies
0 Companies
0 Drugs
Success rate
D000793:Angioid streaks
0 Companies
0 Drugs
Success rate
D003930:Diabetic retinopathy
D012162:Retinal degeneration
0 Companies
0 Drugs
Success rate
D012163:Retinal detachment
0 Companies
0 Drugs
Success rate
D012166:Retinal hemorrhage
0 Companies
0 Drugs
Success rate
D012167:Retinal perforations
0 Companies
0 Drugs
Success rate
D012170:Retinal vein occlusion
D012173:Retinitis
0 Companies
0 Drugs
Success rate
D012178:Retinopathy of prematurity
0 Companies
0 Drugs
Success rate
D015356:Retinal artery occlusion
0 Companies
0 Drugs
Success rate
D015792:Retinal dysplasia
0 Companies
0 Drugs
Success rate
D015861:Retinal neovascularization
0 Companies
0 Drugs
Success rate
D018630:Proliferative vitreoretinopathy
0 Companies
0 Drugs
Success rate
D019572:Retinal neoplasms
0 Companies
0 Drugs
Success rate
D019773:Epiretinal membrane
0 Companies
0 Drugs
Success rate
D031300:Retinal vasculitis
0 Companies
0 Drugs
Success rate
D056833:Central serous chorioretinopathy
0 Companies
0 Drugs
Success rate
D058437:Hypertensive retinopathy
0 Companies
0 Drugs
Success rate
D058456:Retinal telangiectasis
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Inceptua | Ocriplasmin | Jetrea | 2013-03-13 | |||
| Oxurion | Ocriplasmin | Jetrea | 2012-10-17 |
Clinical Trials
Historical Success Rate
Phase 1
54%7/13
Phase 2
27%3/11
Phase 3
31%8/26
Approved: 2Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use